Nasal spray which could fight Covid and other respiratory infections gets funding
MRCF 5 - MRCF5 provides seed stage investment for early-stage life science opportunities associated with MRCF Member organisations. MRCF5 has the capacity to continue to support opportunities into clinical development and commercialisation.
MRCF BTF - The MRCF BTF is focussed on supporting clinical stage, Australian, biomedical opportunities.
MRCF3 - MRCF3 provides seed stage investment for early-stage life science opportunities associated with MRCF Member organisations. MRCF3 has the capacity to continue to support opportunities into clinical development and commercialisation.
MRCF1 and MRCF2 (MRCF IIF, LP and MRCF Trust) - now fully invested
Brandon Biosciences Fund 1 (BBF1 IIF and BBF1 Trust) - now fully invested
George Medicines is an innovative late-stage drug development company focused on the large, expanding and underserved market for the management of non-communicable diseases (NCDs)
High Quality Serum for Biochemistry Analysis: A proprietary blood collection tube rapidly providing high quality serum for analysis from all bloods including anti-coagulated.
Ena Respiratory is a biotechnology company aiming to transform the treatment and prevention of respiratory infections. The company initial focus is to target respiratory infections in patients with asthma and COPD.
Osprey Medical’s DyeVert™ Plus System reduces contrast media in order to make angiography safer for Chronic Kidney Disease (CKD) patients.
Myricx Pharma Launches with £4.5M (AU$8.2M) Financing to Progress its Novel NMT inhibitors in Cancer
PolyActiva successfully completes initial clinical trial with Latanoprost FA SR Ocular Implant delivering glaucoma treatment to patients over a six-month period